Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

NCT01863459 is registered in ClinicalTrials.gov with Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada as lead sponsor.

NCT NCT01863459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Lead sponsor
Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2013
Completion date
March 31, 2017
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult attention deficit hyperactivity disorder (adhd) with co-occuring anxiety and depressive disorders